Skip to contentE
Endovia Health Sciences, Inc.
E
EDVAEndovia Health Sciences, Inc. Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$2.78M$2.78Mderived+124.1% vs Q4 2020 Net Income-$5.88M-$5.88MderivedN/M vs Q4 2020 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endovia Health Sciences, Inc. · CIK 1553788 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$1,675,439N/M Operating Incomederived-$5,754,057N/M Operating Cash Flowderived-$3,081,882N/M Free Cash Flowderived-$3,081,882N/M Margins · derivedGross margin60.2%+74.6 pt vs Q4 2020
Operating margin-206.7%+882.9 pt vs Q4 2020
Net margin-211.2%+1622.1 pt vs Q4 2020
ended Dec 31, 2021 · filed Mar 31, 2022 · 90 d after period end